Consequently, evaluation of TMEM44‐AS1 expression was the effective approach to judgment high‐risk 5‐FU‐resistant GC cases, and clinicians could optimize clinical decisions based on the evaluation results, which might favor a more aggressive treatment regimen. This evidence concerns the gene TMEM44 and gastric cancer.